Handel Synaptogenix, Inc. - SNPX CFD
Føj til favorit- Opsummering
- Historisk Data
- Begivenheder
- Resultatopgørelse
- Saldo
- Cash flow
- Ejerskab
Handelsbetingelser
| Spænd | - | ||||||||
|
Long position, gebyr natten over
Long position overnight fee
Gå til platform | -0.030779% | ||||||||
|
Short position, gebyr natten over
Short position overnight fee
Gå til platform | -0.013666% | ||||||||
| Gebyr natten over, tid | 22:00 (UTC) | ||||||||
| Min. handlet mængde | 1 | ||||||||
| Valuta | USD | ||||||||
| Margen | 20% | ||||||||
| Aktiebørs | United States of America | ||||||||
| Kommission på handel | 0% |
*Information provided by Capital.com
Nøglestatistikker
| Tidligere luk* | N/A |
| Åben* | N/A |
| 1-Års Ændring* | N/A |
| Dagens Spænd* | N/A |
| 52-Ugers Spænd | 0.96-9.98 |
| Gennemsnitlig Volumen (10 dage) | 78.91K |
| Gennemsnitlig Volumen (3 måneder) | 3.77M |
| Market Cap | 7.99M |
| P/E-forhold | -100.00K |
| Udestående aktier | 6.85M |
| Omsætning | N/A |
| EPS | -2.07 |
| Dividend (Udbytte %) | N/A |
| Beta | -100.00K |
| Næste indtjeningsopgørelse | N/A |
Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Luk | Change | Change (%) | Åben | High | Low |
|---|
Synaptogenix, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Årlig
- Pr kvartal
| 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|
| Total omsætning | 0 | 0 | 0 | 0 |
| Totale Driftsudgifter | 11.1494 | 15.5135 | 12.8564 | 12.6183 |
| Salgs/Generelle/Admin. Udgifter, Total | 6.26383 | 10.9725 | 8.08738 | 8.28189 |
| Forskning & Udvikling | 4.88556 | 4.54095 | 3.06903 | 4.33641 |
| Driftsindtægter | -11.1494 | -15.5135 | -12.8564 | -12.6183 |
| Renteindkomst (Udgift), Netto Ikke-Drift | 0.12711 | 0.37871 | 0.15321 | 0.00711 |
| Netto Indkomst Før Skat | -11.0223 | -15.1348 | -12.7032 | -12.6112 |
| Netto Indkomst Efter Skat | -11.0223 | -15.1348 | -12.7032 | -12.6112 |
| Netto Indkomst Før Ekstra Ting | -11.0223 | -15.1348 | -12.7032 | -12.6112 |
| Netto Indkomst | -11.0223 | -15.1348 | -12.7032 | -12.6112 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -11.0223 | -15.1348 | -15.1302 | -12.6112 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -11.0223 | -15.1348 | -15.1302 | -12.6112 |
| Fortyndet Netto Indkomst | -11.0223 | -15.1348 | -15.1302 | -12.6112 |
| Fortyndet Vægtet Gennemsnit Aktier | 1.32211 | 1.32211 | 1.25758 | 5.0151 |
| Fortyndet EPS Uden Ekstraordinære Ting | -8.33687 | -11.4474 | -12.0312 | -2.51465 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | |
| Fortyndet Normaliseret EPS | -8.33687 | -11.4474 | -10.6794 | -2.51465 |
| Usædvanlig Udgift (Indkomst) | 1.7 | 0 | ||
| Total Adjustments to Net Income | -2.427 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Total omsætning | 0 | 0 | 0 | 0 | 0 |
| Totale Driftsudgifter | 3.15519 | 2.29517 | 2.92938 | 4.23856 | 3.28253 |
| Salgs/Generelle/Admin. Udgifter, Total | 2.00341 | 1.30889 | 2.09266 | 2.87693 | 1.79646 |
| Forskning & Udvikling | 1.15178 | 0.98628 | 0.83672 | 1.36164 | 1.48607 |
| Driftsindtægter | -3.15519 | -2.29517 | -2.92938 | -4.23856 | -3.28253 |
| Renteindkomst (Udgift), Netto Ikke-Drift | 0.00082 | 0.00133 | 0.00245 | 0.00252 | 0.00461 |
| Netto Indkomst Før Skat | -3.15438 | -2.29384 | -2.92693 | -4.23605 | -3.27792 |
| Netto Indkomst Efter Skat | -3.15438 | -2.29384 | -2.92693 | -4.23605 | -3.27792 |
| Netto Indkomst Før Ekstra Ting | -3.15438 | -2.29384 | -2.92693 | -4.23605 | -3.27792 |
| Netto Indkomst | -3.15438 | -2.29384 | -2.92693 | -4.23605 | -3.27792 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -3.15438 | -2.29384 | -2.92693 | -4.23605 | -3.27792 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -3.15438 | -2.29384 | -2.92693 | -4.23605 | -3.27792 |
| Fortyndet Netto Indkomst | -3.15438 | -2.29384 | -2.92693 | -4.23605 | -3.27792 |
| Fortyndet Vægtet Gennemsnit Aktier | 2.96903 | 3.9712 | 6.1966 | 6.7998 | 6.9392 |
| Fortyndet EPS Uden Ekstraordinære Ting | -1.06243 | -0.57762 | -0.47234 | -0.62297 | -0.47238 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Fortyndet Normaliseret EPS | -1.06243 | -0.57762 | -0.47234 | -0.62297 | -0.47238 |
| Usædvanlig Udgift (Indkomst) | 0 |
- Årlig
- Pr kvartal
| 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|
| Totale Nuværende Aktiver | 29.4575 | 17.8762 | 6.72879 | 35.5042 |
| Likvider og Kortsigtede Investeringer | 28.8542 | 17.382 | 5.79506 | 34.214 |
| Likvider & Lignende | 28.8542 | 17.382 | 5.79506 | 34.214 |
| Prepaid Expenses | 0.60332 | 0.49411 | 0.80629 | 1.29023 |
| Total Assets | 29.4784 | 17.8978 | 6.751 | 35.5247 |
| Property/Plant/Equipment, Total - Net | 0.02084 | 0.02167 | 0.02221 | 0.02045 |
| Total Current Liabilities | 2.95708 | 0.47906 | 1.61249 | 1.99491 |
| Accounts Payable | 2.89858 | 0.41308 | 1.26034 | 1.29651 |
| Accrued Expenses | 0.05849 | 0.06598 | 0.35215 | 0.69841 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 |
| Total Liabilities | 2.95708 | 0.47906 | 1.61249 | 1.99491 |
| Total Long Term Debt | 0 | 0 | 0 | 0 |
| Total Equity | 26.5213 | 17.4188 | 5.13851 | 33.5298 |
| Common Stock | 0.00129 | 0.00131 | 0.0005 | 0.00067 |
| Additional Paid-In Capital | 100.202 | 106.234 | 6.66848 | 47.6707 |
| Retained Earnings (Accumulated Deficit) | -73.6821 | -88.8168 | -1.53047 | -14.1417 |
| Total Liabilities & Shareholders’ Equity | 29.4784 | 17.8978 | 6.751 | 35.5247 |
| Total Common Shares Outstanding | 1.32211 | 1.32211 | 1.25758 | 6.73018 |
| Totale Tilgodehavender, Netto | 0.12745 | |||
| Other Equity, Total | 0 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Totale Nuværende Aktiver | 16.3257 | 32.9402 | 32.3402 | 35.5042 | 32.3342 |
| Likvider og Kortsigtede Investeringer | 14.8484 | 31.7021 | 31.2946 | 34.214 | 31.2817 |
| Likvider & Lignende | 14.8484 | 31.7021 | 31.2946 | 34.214 | 31.2817 |
| Totale Tilgodehavender, Netto | 0 | 0 | |||
| Prepaid Expenses | 1.47723 | 1.23816 | 1.04551 | 1.29023 | 1.05247 |
| Total Assets | 16.3466 | 32.96 | 32.3586 | 35.5247 | 32.3533 |
| Property/Plant/Equipment, Total - Net | 0.02097 | 0.01973 | 0.01849 | 0.02045 | 0.01913 |
| Total Current Liabilities | 0.93744 | 0.76997 | 1.00733 | 1.99491 | 0.66934 |
| Accounts Payable | 0.75896 | 0.64816 | 0.93538 | 1.29651 | 0.40135 |
| Accrued Expenses | 0.17848 | 0.12181 | 0.07195 | 0.69841 | 0.26799 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 0.93744 | 0.76997 | 1.00733 | 1.99491 | 0.66934 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 15.4092 | 32.19 | 31.3513 | 33.5298 | 31.684 |
| Common Stock | 0.0014 | 0.0006 | 0.00062 | 0.00067 | 0.00068 |
| Additional Paid-In Capital | 20.0927 | 39.1681 | 41.2563 | 47.6707 | 49.1029 |
| Retained Earnings (Accumulated Deficit) | -4.68485 | -6.97869 | -9.90563 | -14.1417 | -17.4196 |
| Total Liabilities & Shareholders’ Equity | 16.3466 | 32.96 | 32.3586 | 35.5247 | 32.3533 |
| Total Common Shares Outstanding | 3.50813 | 6.0388 | 6.13697 | 6.73018 | 6.80965 |
- Årlig
- Pr kvartal
| 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|
| Netto indkomst/Startlinje | -11.0223 | -15.1348 | -12.7032 | -12.6112 |
| Likvider Fra Driftsaktiviteter | -7.69677 | -11.8868 | -8.1024 | -8.71073 |
| Likvider Fra Driftsaktiviteter | 0.003 | 0.00439 | 0.00487 | 0.00497 |
| Ikke-Likvide Ting | 2.21661 | 5.61236 | 3.90212 | 3.86958 |
| Ændringer i Driftskapital | 1.10591 | -2.36881 | 0.69381 | 0.02593 |
| Likvider fra Investeringsaktiviteter | -0.00319 | -0.00521 | -0.00541 | -0.0032 |
| Kapitaludgifter | -0.00319 | -0.00521 | -0.00541 | -0.0032 |
| Likvider fra Financieringsaktiviteter | 20.441 | 0.41984 | -3.47917 | 37.1329 |
| Udstedelse (Pensionering) af Aktier, Netto | 20.441 | 0.41984 | 16.5242 | 37.1344 |
| Netto Ændring i Likviditet | 12.7411 | -11.4722 | -11.587 | 28.4189 |
| Financiering af Cash-Flow-Ting | -20.0034 | -0.00153 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -3.15438 | -5.44822 | -8.37515 | -12.6112 | -3.27792 |
| Cash From Operating Activities | -3.58672 | -5.58532 | -6.66556 | -8.71073 | -3.48541 |
| Cash From Operating Activities | 0.00125 | 0.00249 | 0.00373 | 0.00497 | 0.00132 |
| Non-Cash Items | 0.91241 | 1.1348 | 2.4228 | 3.86958 | 0.87901 |
| Changes in Working Capital | -1.34599 | -1.27439 | -0.71694 | 0.02593 | -1.08781 |
| Cash From Investing Activities | 0 | 0 | 0 | -0.0032 | |
| Capital Expenditures | 0 | 0 | 0 | -0.0032 | |
| Cash From Financing Activities | 12.6401 | 31.4923 | 32.1651 | 37.1329 | 0.55315 |
| Financing Cash Flow Items | 0.12745 | 0.12592 | -0.00153 | -0.00153 | 0 |
| Issuance (Retirement) of Stock, Net | 12.5127 | 31.3664 | 32.1667 | 37.1344 | 0.55315 |
| Net Change in Cash | 9.0534 | 25.907 | 25.4996 | 28.4189 | -2.93226 |
| Investornavn | Investortype | Procent udestående | Aktiebeholdning | Aktieændring | Beholdningsdato | IOmsætningsscore |
|---|---|---|---|---|---|---|
| Intracoastal Capital, L.L.C. | Corporation | 6.7474 | 490339 | 225333 | 2021-12-31 | LOW |
| Alpha Capital Aktiengesellschaft | Holding Company | 4.1554 | 301977 | -29305 | 2021-12-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.0617 | 222495 | 5659 | 2022-09-30 | LOW |
| Cannell & Co. | Investment Advisor | 1.0488 | 76220 | 0 | 2022-09-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.8597 | 62475 | 0 | 2022-09-30 | LOW |
| Perry (George) | Individual Investor | 0.5504 | 40000 | 40000 | 2021-07-13 | |
| Silverman (Joshua) | Individual Investor | 0.5262 | 38238 | 33238 | 2022-12-20 | MED |
| Alkon (Daniel L M.D.) | Individual Investor | 0.4892 | 35547 | 34062 | 2022-12-20 | |
| Weinstein (Robert) | Individual Investor | 0.4568 | 33198 | 33000 | 2022-12-20 | HIGH |
| Singer (William S) | Individual Investor | 0.4541 | 33000 | 33000 | 2022-12-20 | HIGH |
| Tuchman (Alan J) | Individual Investor | 0.4541 | 33000 | 33000 | 2022-12-20 | LOW |
| Bernstein (Bruce T.) | Individual Investor | 0.3795 | 27578 | 27500 | 2022-12-20 | LOW |
| Schechter (Jonathan L) | Individual Investor | 0.375 | 27250 | 24750 | 2022-12-20 | HIGH |
| Diametric Capital | Investment Advisor/Hedge Fund | 0.3653 | 26549 | -1172 | 2022-09-30 | HIGH |
| Platform Technology Partners LLC | Investment Advisor | 0.3459 | 25138 | 9106 | 2022-12-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.2766 | 20100 | 0 | 2022-09-30 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.2271 | 16500 | 600 | 2022-09-30 | HIGH |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.2042 | 14840 | 297 | 2022-09-30 | LOW |
| Prelude Capital Management, LLC | Hedge Fund | 0.1387 | 10081 | -4283 | 2022-09-30 | HIGH |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.1297 | 9422 | -4 | 2022-12-31 | LOW |
Hvorfor vælge Capital.com? Vores tal taler for sig selv.
Capital.com Group +485000+
Handlende
65000+
Månedlkige, aktive klienter
$48000000+
Månedlig investeringsvolumen
$28000000+
Prøv nu Hævet hver måned
Handelslommeregner
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Handelskurtage
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Gearing
20:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Handelsstørrelse (Gearing x Investering):
Åben
Luk
Short Long
Synaptogenix, Inc. Company profile
Om Synaptogenix, Inc.
Synaptogenix, Inc. tidligere Neurotrope BioScience, Inc. er en biofarmaceutisk virksomhed. Selskabet fokuserer hovedsageligt på udvikling af terapier til patienter med neurodegenerative sygdomme og udviklingsforstyrrelser. Selskabet er ved at udvikle en produktplatform baseret på en lægemiddelkandidat kaldet Bryostatin-1, som er syntetiseret fra et naturprodukt (bryostatin), der er isoleret fra en marine hvirvelløse dyr, til behandling af Alzheimers sygdom (AD). Den vigtigste produktkandidat er bryostatin-1. Bryostatin-1 er en protein kinase C Epsilon (PKC e), en og e aktivator, der oprindeligt blev udviklet som et potentielt middel mod kræft. Selskabet evaluerer også terapeutiske anvendelser af bryostatin til andre neurodegenerative eller kognitive sygdomme og dysfunktioner, såsom Fragile X-syndromet, multipel sklerose og Niemann-Pick type C-sygdom, som har været genstand for prækliniske forsøg.
| Industry: | Biotechnology & Medical Research (NEC) |
1185 Avenue Of The Americas, 3Rd Floor
NEW YORK
NEW YORK 10036
US
Resultatopgørelse
- Annual
- Quarterly
Folk ser også
Leder du stadig efter en mægler, du kan stole på?
Deltag sammen med 485.000+ handlende over hele verden, der valgte at handle hos Capital.com